News story: Employed Bar Awards 2018

□□Two GLD lawyers have won prestigious accolades at the Bar Council Employed Bar Awards. The winners were announced at a ceremony held at the Imperial War Museum in London, on Friday 29 June.

Top award

Katherine Willerton from the Department for Exiting the European Union (DExEU) Legal Advisers team was named 'Employed barrister of the year' for her work on the European Union (Withdrawal) Bill. Katherine is the deputy team leader in the Legislation team of 12 lawyers who worked with ministers and officials to produce the Bill and get it through Parliament. The nomination referred to her drive and resilience as well as her 'superb legal analysis and advice'. She was recognised for her substantial contribution to the rewriting of the UK constitution, in circumstances of political controversy and sensitivity.

Outstanding achievement

Aoife Drudy who works in the Home Office Legal Advisers (HOLA) team has won the award for 'Outstanding achievement by a public service barrister'. She has been the lead lawyer advising the Northern Ireland Office on the EU Exit negotiations and led on technical discussions with the EU Commission and Irish Government The nomination said her legal skills and practical advice have been widely admired across government, making her an essential component of the UK's negotiating team.

Further finalist

A third GLD lawyer, Jonathan Orde, was one of the finalists in the 'Young employed barrister of the year' category. The nomination, sent in on his behalf, speaks of his contribution to increasing advocacy opportunities in GLD and the fact that as a direct result of the success he had in court as a pupil, all GLD pupils undertake advocacy during their second 6 secondment to Chambers.

High standard

Treasury Solicitor, Jonathan Jones was on the judging panel and said he was highly impressed by the standard of the entries in this, only the second year of the Employed Bar Awards:

Congratulations to the GLD winners, Katherine and Aoife, for their outstanding success in winning their categories and to Jonathan for being short-listed in his category.

As a member of the judging panel I was, of course, scrupulously neutral (I played no part in the shortlisting) and found the standard of entries to be high right across the employed bar. I am

particularly proud of all our GLD finalists, who exemplify the brilliant work we do in $\mathsf{GLD}.\square$

The full list of those shortlisted and all category winners can be found on the Bar Council website.

News story: Essex healthcare firm to double overseas exports

BioSure, an Essex healthcare company that manufactured the first home testing HIV kit is expected to more than double its exporting sales in the next year as it expands in South Africa.

BioSure's kits require the user to simply prick their finger for a small drop of blood, which is then placed in the device. The process detects specific antibodies in the blood sample and produces an extremely accurate result in just fifteen minutes. The company, which was founded in 2011, originally supplied its product to hospitals and doctors across the United Kingdom, and in 2015 started selling its kits directly to individuals.

BioSure completed its first international order last year, seeing its products sold in over 500 pharmacies in South Africa. Demand for its products in the region has grown month-on-month since, and combined with other markets, exporting accounts for 40% of the firm's sales. This figure is set to grow to 90% in the next year as the business expand into new markets including Kenya and Brazil.

The business has worked closely with specialist trade advisers at the Department for International Trade (DIT) ahead of securing its first South African contract. DIT has also provided international market research and put BioSure in touch with distributors and potential buyers in East Africa and South America.

Brigette Bard, Founder of BioSure, said:

Our self-testing HIV kits are the first step in helping people get diagnosed and support the United Nations' ambitious pledge to help end the HIV / AIDS epidemic. Its pledge aims that by 2020, 90% of all people diagnosed with HIV will receive treatment.

Exporting our kits was always part of our business plan — a goal we achieved last year with our first contract in South Africa where the virus is most prevalent. Since then, we've gone from strength to strength and now plan to establish our products in South America

for the first time, as well as make inroads in East and West Africa.

When exporting to different international markets, it's vital to ensure the regulatory and tax landscapes have been thoroughly researched. As a healthcare business, all our products go through rigorous testing to comply with that specific country's regulation. Expert organisations like DIT can help navigate this process. If we can do it, so can many other local firms.

Alan Pain, Head of Exports for DIT East of England, said:

International expansion was always a great option for BioSure and we're proud to have supported its venture in South Africa and beyond. Exporting is a multifaceted process, particularly for healthcare brands, so thorough research is vital.

Firms should ensure they have processes in place to deal with language barriers, as well as differing tax and regulatory landscapes. While exporting can sometimes seem daunting for firms, particularly those with limited resources, they shouldn't feel like they have to go through the process alone.

We have more than 30 international trade advisers located across the East of England to support ambitious businesses looking to tap into the emerging opportunities overseas. The support is out there, and I'd urge anyone who is interested to get in touch.

News story: Essex healthcare firm to double overseas exports

BioSure, an Essex healthcare company that manufactured the first home testing HIV kit is expected to more than double its exporting sales in the next year as it expands in South Africa.

BioSure's kits require the user to simply prick their finger for a small drop of blood, which is then placed in the device. The process detects specific antibodies in the blood sample and produces an extremely accurate result in just fifteen minutes. The company, which was founded in 2011, originally supplied its product to hospitals and doctors across the United Kingdom, and in 2015 started selling its kits directly to individuals.

BioSure completed its first international order last year, seeing its products sold in over 500 pharmacies in South Africa. Demand for its products

in the region has grown month-on-month since, and combined with other markets, exporting accounts for 40% of the firm's sales. This figure is set to grow to 90% in the next year as the business expand into new markets including Kenya and Brazil.

The business has worked closely with specialist trade advisers at the Department for International Trade (DIT) ahead of securing its first South African contract. DIT has also provided international market research and put BioSure in touch with distributors and potential buyers in East Africa and South America.

Brigette Bard, Founder of BioSure, said:

Our self-testing HIV kits are the first step in helping people get diagnosed and support the United Nations' ambitious pledge to help end the HIV / AIDS epidemic. Its pledge aims that by 2020, 90% of all people diagnosed with HIV will receive treatment.

Exporting our kits was always part of our business plan — a goal we achieved last year with our first contract in South Africa where the virus is most prevalent. Since then, we've gone from strength to strength and now plan to establish our products in South America for the first time, as well as make inroads in East and West Africa.

When exporting to different international markets, it's vital to ensure the regulatory and tax landscapes have been thoroughly researched. As a healthcare business, all our products go through rigorous testing to comply with that specific country's regulation. Expert organisations like DIT can help navigate this process. If we can do it, so can many other local firms.

Alan Pain, Head of Exports for DIT East of England, said:

International expansion was always a great option for BioSure and we're proud to have supported its venture in South Africa and beyond. Exporting is a multifaceted process, particularly for healthcare brands, so thorough research is vital.

Firms should ensure they have processes in place to deal with language barriers, as well as differing tax and regulatory landscapes. While exporting can sometimes seem daunting for firms, particularly those with limited resources, they shouldn't feel like they have to go through the process alone.

We have more than 30 international trade advisers located across the East of England to support ambitious businesses looking to tap into the emerging opportunities overseas. The support is out there, and I'd urge anyone who is interested to get in touch. <u>Firms looking for support should visit great.gov.uk</u> which has around 1,000 live export opportunities currently listed and includes general information on exporting and events.

News story: £215 million research fund to tackle the next generation of health challenges

Health and Social Care Secretary Jeremy Hunt has announced a £215 million package of funding for research that could transform the lives of millions of people who are living with a range of conditions, including life-long illnesses, mental health issues and obesity.

Leading academics and technology experts will be able to apply for research funding to develop health solutions for the future that give patients greater independence and choice about how they manage their healthcare.

An investment of £150 million will fund research over the next 5 years to tackle important emerging issues, including the pressures of an ageing population and the increasing demands on the NHS.

The remaining £65 million will go towards 13 National Institute for Health Research policy research units that will play a vital role in making sure the government and arm's length bodies have the best possible information and evidence available when making policy decisions about health and social care.

The units will cover a range of specialisms and conditions, including:

- behavioural science
- adult social care
- older people and frailty
- cancer awareness, screening and early diagnosis

Each university-based unit will host a multidisciplinary team of researchers from collaborating institutions to create a critical mass of experts for research in priority areas for health and social care policy.

An extra £3 million will also be invested in the creation of a new research leader programme for nurses and midwives. Their role will help to influence new approaches to health and care and improve patient experience.

Health and Social Care Secretary Jeremy Hunt said:

As the NHS celebrates its 70th birthday, more people than ever before are living longer lives thanks to the dedication of

hardworking staff. It is therefore vital we harness technology to develop the next generation of innovative treatments as part of the government's long-term plan for the NHS.

That's why I want our world-leading academics, researchers and technology experts to work with frontline staff to develop the innovations which not only allow people to live longer, but also to lead healthier lives, so the NHS can continue to provide world-class care to all.

Health Minister Lord O'Shaughnessy said:

With a growing and ageing population, maintaining a world-class NHS depends on harnessing the discoveries of cutting-edge research and rapidly bringing them into everyday healthcare.

The UK has a proud tradition of ground-breaking medical R&D and this funding means our country can continue to lead the world.

News story: £215 million research fund to tackle the next generation of health challenges

Health and Social Care Secretary Jeremy Hunt has announced a £215 million package of funding for research that could transform the lives of millions of people who are living with a range of conditions, including life-long illnesses, mental health issues and obesity.

Leading academics and technology experts will be able to apply for research funding to develop health solutions for the future that give patients greater independence and choice about how they manage their healthcare.

An investment of £150 million will fund research over the next 5 years to tackle important emerging issues, including the pressures of an ageing population and the increasing demands on the NHS.

The remaining £65 million will go towards 13 National Institute for Health Research policy research units that will play a vital role in making sure the government and arm's length bodies have the best possible information and evidence available when making policy decisions about health and social care.

The units will cover a range of specialisms and conditions, including:

- behavioural science
- adult social care
- older people and frailty
- cancer awareness, screening and early diagnosis

Each university-based unit will host a multidisciplinary team of researchers from collaborating institutions to create a critical mass of experts for research in priority areas for health and social care policy.

An extra £3 million will also be invested in the creation of a new research leader programme for nurses and midwives. Their role will help to influence new approaches to health and care and improve patient experience.

Health and Social Care Secretary Jeremy Hunt said:

As the NHS celebrates its 70th birthday, more people than ever before are living longer lives thanks to the dedication of hardworking staff. It is therefore vital we harness technology to develop the next generation of innovative treatments as part of the government's long-term plan for the NHS.

That's why I want our world-leading academics, researchers and technology experts to work with frontline staff to develop the innovations which not only allow people to live longer, but also to lead healthier lives, so the NHS can continue to provide world-class care to all.

Health Minister Lord O'Shaughnessy said:

With a growing and ageing population, maintaining a world-class NHS depends on harnessing the discoveries of cutting-edge research and rapidly bringing them into everyday healthcare.

The UK has a proud tradition of ground-breaking medical R&D and this funding means our country can continue to lead the world.